The role of hyperbaric oxygen therapy in the treatment of radiation lesions

Gaio-Lima, Clara; Castedo, João; Cruz, Mafalda; Candeias, Margarida; Camacho, Óscar

doi:10.1007/s12094-022-02892-x

Cited by 4 publications

(5 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there was a trend for hematochezia resolution after completing at least 70 HBOT sessions. In general, the number of sessions performed in our study was higher than in other studies that present a full course treatment with an average of 40 sessions ( 42 , 49 , 61 ). This higher number of prescribed sessions may be explained by the fact that we treat more severe cases of RIP, as patients come to us in later phases and, consequently, with more refractory symptoms.…”

Section: Discussioncontrasting

confidence: 66%

The effectiveness of hyperbaric oxygen therapy for managing radiation-induced proctitis – results of a 10-year retrospective cohort study

et al. 2023

View full text Add to dashboard Cite

IntroductionDespite modern radiotherapy (RT) techniques, radiation-induced proctitis (RIP) remains a significant complication of RT for pelvic organ malignancies. Over the last decades, an enormous therapeutic armamentarium has been considered in RIP, including hyperbaric oxygen therapy (HBOT). However, the evidence regarding the impact of HBOT on RIP is conflicting. This study aims to evaluate the effectiveness and safety of HBOT in the treatment of RIP.MethodsTen-year (2013-2023) retrospective analysis of all consecutive patients with RIP treated with HBOT at Centro de Medicina Subaquática e Hiperbárica (CMSH) (Armed Forces Hospital – Lisbon, Portugal). Patients were exposed to 100% oxygen at 2.5 ATA, in a multiplace first-class hyperbaric chamber, for 70-min periods, once daily, five times per week. Fisher’s exact test was performed using SPSS (version 23.0); p<0.05 was accepted as statistically significant.ResultsOf a total of 151 patients with RIP, 88 were included in the final analysis, of whom 38.6% evidenced other concurrent radiation-induced soft tissue lesions. The most reported primary pelvic tumor treated with RT was prostate cancer (77.3%), followed by cervical cancer (10.2%). Hematochezia was the most observed clinical manifestation (86.4%). After a median of 60 HBOT sessions (interquartile range [IQR]: 40-87.5), 62.5% and 31.8% of patients achieved a clinical complete and partial response, respectively, with a hematochezia resolution rate of 93.7% (complete or partial). While partial and complete responses require fewer than 70 sessions of HBOT in terms of overall RIP symptoms (p=0.069), isolated hematochezia tends to require at least 70 sessions (p=0.075). Individuals with at least two concurrent late radiation tissue injuries were associated with a complete response to HBOT (p=0.029). Only about 5.7% of patients did not respond to the treatment. Eighteen patients (20.5%) developed reversible ear barotrauma. The number of HBOT sessions was a predictor of HBOT side effects (odds ratio: 1.010; 95% confidence interval, 1.000-1.020; p=0.047).ConclusionThe HBOT proved to be an effective and safe treatment for RIP refractory to medical and/or endoscopic treatments. This real-world evidence study adds value to published data on the management of RIP with HBOT.

show abstract

Section: Discussioncontrasting

confidence: 66%

The effectiveness of hyperbaric oxygen therapy for managing radiation-induced proctitis – results of a 10-year retrospective cohort study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The subjective parameters of 22 patients before and after HBOT were analyzed, and 15 patients showed improvement (decreased score on the Late Effects Normal Tissue Task Force-Subjective, Objective, Management, Analytic scale). Five patients maintained the same score, and two patients worsened [46]. It is important to note that limitations in the number of hyperbaric oxygen chambers limit the accessibility of this treatment.…”

Section: Hyperbaric Oxygen Therapymentioning

confidence: 94%

Research progress and treatment of radiation enteritis and gut microbiota

Ren

Sun

et al. 2023

Radiat Oncol J

View full text Add to dashboard Cite

Radiation enteritis is a kind of intestinal radiation injury in patients with pelvic and retroperitoneal malignancies after radiotherapy, and its occurrence and development process are very complicated. At present, studies have confirmed that intestinal microecological imbalance is an important factor in the formation of this disease. Abdominal radiation causes changes in the composition of the flora and a decrease in its diversity, which is mainly manifested by a decrease in beneficial bacterial species such as Lactobacilli and Bifidobacteria. Intestinal dysbacteriosis aggravates radiation enteritis, weakens the function of the intestinal epithelial barrier, and promotes the expression of inflammatory factors, thereby aggravating the occurrence of enteritis. Given the role of the microbiome in radiation enteritis, we suggest that the gut microbiota may be a potential biomarker for the disease. Treatment methods such as probiotics, antibiotics, and fecal microbiota transplantation are ways to correct the microbiota and may be an effective way to prevent and treat radiation enteritis. Based on a review of the relevant literature, this paper reviews the mechanism and treatment of intestinal microbes in radiation enteritis.

show abstract

“…Treatment for adults usually requires pressurisation to 2.0-3.0 ATA for 60-120 min once or twice a day; however, for infants or patients with serious underlying diseases and unstable vital signs, treatment usually requires pressurisation to 1.5-1.8 ATA. 27 As a reliable treatment, HBOT is widely used to treat various diseases, including decompression sickness, carbon monoxide poisoning, femoral head necrosis, skin grafts and flaps, radiationinduced injuries, diabetic foot, among others. [28][29][30][31][32][33] During the treatment period, patients typically have arterial partial pressures of oxygen greater than 2000 mm Hg and tissue partial pressures of oxygen between 200 mm Hg and 400 mm Hg.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

“…The oxygen chamber pressure and treatment duration are determined according to the patient’s condition. Treatment for adults usually requires pressurisation to 2.0–3.0 ATA for 60–120 min once or twice a day; however, for infants or patients with serious underlying diseases and unstable vital signs, treatment usually requires pressurisation to 1.5–1.8 ATA 27. As a reliable treatment, HBOT is widely used to treat various diseases, including decompression sickness, carbon monoxide poisoning, femoral head necrosis, skin grafts and ﬂaps, radiation-induced injuries, diabetic foot, among others 28–33.…”

Section: Introductionmentioning

confidence: 99%

“…With the continuous development of technology, HBOT has proven to be a highly effective and safe method to treat various diseases. 27 36 Most side effects observed during treatments are mild and reversible, with the most common side effect being middle ear barotrauma, which occurs when the patient’s middle ear pressure is not equalised. 37 Studies have confirmed the positive effect of HBOT in the treatment of different types of pain, such as complex regional pain syndrome and migraine.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hyperbaric oxygen therapy for patients with fibromyalgia: a systematic review protocol

Han

Yuan

et al. 2023

BMJ Open

View full text Add to dashboard Cite

IntroductionFibromyalgia (FM) is an unexplained chronic condition characterised by generalised pain, sleep disturbances, autonomic disturbances, anxiety, fatigue and cognitive impairment. FM is a prevalent chronic disease worldwide that imposes a significant burden on individuals and society. Emerging evidence suggests that environmental interventions, such as exposure to hyperbaric oxygen therapy (HBOT), can relieve pain and improve the quality of life in patients with FM. This study will systematically and comprehensively assess the effectiveness and safety of HBOT in patients with FM and provide evidence to support its implementation. We hope that the final review will be helpful in supporting the decision-making processes related to treatment programmes.Methods and analysisThis protocol is reported in accordance with the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols guidelines. Ten key databases, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE (Excerpt Medica Database), PsycINFO, CINAHL (Cumulative Index to Nursing and Allied Health Literature), PEDro, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, WANFANG and VIP (Chinese Scientific Journal Database), will be searched from inception through December 2022 to identify relevant randomised controlled trials examining the effectiveness of HBOT in patients with FM published in English or Chinese. Two reviewers will independently complete the study screening, selection, and data extraction and assess the risk of bias in the included studies using the 0–10 PEDro Scale. Narrative or quantitative syntheses will be performed and a systematic review and meta-analysis will be performed using Review Manager V.5.3 statistical software.Ethics and disseminationEthical approval was not required for this protocol. The results of the final review will be disseminated in a peer-reviewed journal.PROSPERO registration numberCRD42022363672

show abstract

The role of hyperbaric oxygen therapy in the treatment of radiation lesions

Cited by 4 publications

References 49 publications

The effectiveness of hyperbaric oxygen therapy for managing radiation-induced proctitis – results of a 10-year retrospective cohort study

The effectiveness of hyperbaric oxygen therapy for managing radiation-induced proctitis – results of a 10-year retrospective cohort study

Research progress and treatment of radiation enteritis and gut microbiota

Hyperbaric oxygen therapy for patients with fibromyalgia: a systematic review protocol

Contact Info

Product

Resources

About